Maternal use of non-TNF inhibitor biologic, tofacitinib pose minimal infectious risk to offspring

ATLANTA — The use of either non-TNF inhibitor biologics or tofacitinib for chronic inflammatory diseases during pregnancy did not significantly increase risk for serious infections among infants, according to findings presented at the 2019 ACR/ARP Annual Meeting.“Infants could be exposed to therapeutic and potentially supratherapeutic levels of biologic and small-molecule drugs during pregnancy, leading to concerns that these agents could cause immunosuppression and, therefore, serious infection in offspring,” Evelyne Vinet, MD, PhD, associate professor of rheumatology andRead More

Share on facebook
Share on twitter
Share on linkedin